A senior government official stated that price controls for pharmaceutical formulations and medical devices should be established based on different criteria, as these are distinct product categories.
Despite a government committee preparing to review the Drug (Prices Control) Order (DPCO), 2013, the official, Arunish Chawla, reassured medical device manufacturers that this review would not necessarily result in broader price controls that could harm the industry.
Chawla mentioned that the committee would engage with medical device associations as “special invitees” to understand their perspectives before making any recommendations.
He emphasized the need to differentiate between drugs and medical devices within the regulatory framework, citing differences in development cycles and approval processes.
Chawla highlighted the necessity for a new legal framework to cater to the evolving pharmaceutical and medtech industry while ensuring drug availability and affordability. Lastly, Chawla dismissed speculations about imposing price ceilings on more medical devices.
For more information visit at https://happenrecently.com/zepto/?amp=1
